204 related articles for article (PubMed ID: 29067473)
1. The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.
Lucchesi M; Sardi I; Puppo G; Chella A; Favre C
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1047-1053. PubMed ID: 29067473
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation: checkpoint blockade etc.
Curry WT; Lim M
Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii26-vii31. PubMed ID: 26516223
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract][Full Text] [Related]
4. The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies.
Keung EZ; Wargo JA
Surg Oncol Clin N Am; 2019 Jul; 28(3):369-386. PubMed ID: 31079794
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
Ring EK; Markert JM; Gillespie GY; Friedman GK
Clin Cancer Res; 2017 Jan; 23(2):342-350. PubMed ID: 27836863
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors: Basics and Challenges.
Li B; Chan HL; Chen P
Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
Teng F; Kong L; Meng X; Yang J; Yu J
Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors.
Haanen JB; Robert C
Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoints and cancer in the immunogenomics era.
Park R; Winnicki M; Liu E; Chu WM
Brief Funct Genomics; 2019 Mar; 18(2):133-139. PubMed ID: 30137232
[TBL] [Abstract][Full Text] [Related]
13. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
[TBL] [Abstract][Full Text] [Related]
14. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
15. State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.
Bersanelli M; Buti S; De Giorgi U; Di Maio M; Giannarelli D; Pignata S; Banna GL
Crit Rev Oncol Hematol; 2019 Jul; 139():87-90. PubMed ID: 31112887
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
17. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.
Marabelle A; Gray J
Pediatr Blood Cancer; 2015 Aug; 62(8):1317-25. PubMed ID: 25808079
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
20. Practical Approaches to Immunotherapy in the Clinic.
Agarwala SS
Semin Oncol; 2015 Dec; 42 Suppl 3():S20-7. PubMed ID: 26598056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
